To further accelerate the validation and clinical application of liquid biopsy-based ccfDNA targeted NGS assays, SeraCare has developed the Seraseq ctDNA Complete((TM) that expands coverage of all relevant variant types (SNVs, INDELs, CNVs, and gene fusions) in a single, highly multiplexed reference sample. These new products are offered in either a purified ctDNA format or a plasma-like matrix format, all precisely quantitated by digital PCR against a single well-characterized genomic background (GM24385), and orthogonally validated with NGS technology. This specific ctDNA Complete product has an allele frequency of 2.5%.